ResBiotech Innovation Institute

ResBiotech Innovation Institute is a University of Alabama at Birmingham-affiliated health innovation platform founded in 2020 by physician-scientist C. Vivek Lal. The organization appears to function as a company-building and commercialization vehicle focused on cardio-respiratory and maternal-child health technologies rather than as a single-asset drug developer. Publicly available information indicates that its flagship company is ResBiotic, which is developing probiotic and pharmabiotic products for lung health, including a medical food targeting the gut-lung axis. ResBiotech has been described as an incubator, accelerator, and platform for inventing, creating, and monetizing proprietary medical technologies. Available evidence does not show a broad disclosed clinical-stage pipeline at the institute level.